- Home
- NPCT vs RCEL Comparison
NPCT vs RCEL Comparison
Compare NPCT & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- RCEL
- Stock Information
- Founded
- NPCT 2020
- RCEL N/A
- Country
- NPCT United States
- RCEL United States
- Employees
- NPCT N/A
- RCEL N/A
- Industry
- NPCT Investment Managers
- RCEL Medical/Dental Instruments
- Sector
- NPCT Finance
- RCEL Health Care
- Exchange
- NPCT Nasdaq
- RCEL Nasdaq
- Market Cap
- NPCT 316.6M
- RCEL 136.7M
- IPO Year
- NPCT N/A
- RCEL N/A
- Fundamental
- Price
- NPCT $10.98
- RCEL $5.38
- Analyst Decision
- NPCT
- RCEL Strong Buy
- Analyst Count
- NPCT 0
- RCEL 4
- Target Price
- NPCT N/A
- RCEL $16.50
- AVG Volume (30 Days)
- NPCT 107.1K
- RCEL 296.2K
- Earning Date
- NPCT 01-01-0001
- RCEL 08-07-2025
- Dividend Yield
- NPCT 9.82%
- RCEL N/A
- EPS Growth
- NPCT N/A
- RCEL N/A
- EPS
- NPCT N/A
- RCEL N/A
- Revenue
- NPCT N/A
- RCEL $71,661,000.00
- Revenue This Year
- NPCT N/A
- RCEL $57.16
- Revenue Next Year
- NPCT N/A
- RCEL $36.69
- P/E Ratio
- NPCT N/A
- RCEL N/A
- Revenue Growth
- NPCT N/A
- RCEL 41.35
- 52 Week Low
- NPCT $8.58
- RCEL $4.71
- 52 Week High
- NPCT $10.63
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- NPCT 50.48
- RCEL 49.79
- Support Level
- NPCT $11.13
- RCEL $5.61
- Resistance Level
- NPCT $11.29
- RCEL $6.04
- Average True Range (ATR)
- NPCT 0.12
- RCEL 0.32
- MACD
- NPCT -0.02
- RCEL 0.14
- Stochastic Oscillator
- NPCT 19.51
- RCEL 74.44
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.